In silico screening of FDA-approved drugs for antiviral activity against the influenza virus: a novel approach to the repurposing of existing medications
DOI:
https://doi.org/10.60988/p.v37i2S.204Keywords:
in silico; influenza; lysine; FDA-approved drugs; antiviralAbstract
This study investigated the efficacy of FDA-recognized compounds in preventing influenza virus infections, using in silico analysis. By focusing on the structural characteristics of neuraminidase (a key target in antiviral therapy), the study identified 12 critical regions amenable to drug interaction. Among the evaluated compounds, lysine emerged as the most promising candidate, exhibiting an XP GScore of -9.912 and relatively high binding affinity. Molecular docking simulations revealed that lysine engages essential amino acid residues within the neuraminidase active site through hydrogen bonding and salt-bridge formation, thereby supporting its potential to inhibit viral replication. Other compounds, including iohexol and capastat, also demonstrated notably high binding constants. These findings underscore the feasibility of drug repurposing, particularly involving known dietary supplements such as lysine, as a strategic response to emerging antiviral resistance, severe influenza cases, and seasonal outbreaks. The results provide a preliminary experimental framework to guide future studies and support the clinical deployment of these agents against influenza and related infections.
References
1. Soudani S., Mafi A., Al Mayahi Z., Al Balushi S., Dbaibo G., Al Awaidy S., et al. A systematic review of influenza epidemiology and surveillance in the Eastern Mediterranean and North African region. Infect. Dis. Ther. 11(1), 15–52, 2022. DOI: 10.1007/s40121-021-00534-3
2. Radhi A.H., Ibrahim Z.H., Alhilifi R. The epidemiological pattern of seasonal influenza in four sentinel sites in Iraq. Influenza Other Respir. Viruses 17(4), e13134, 2023. DOI: 10.1111/irv.13134
3. Xu J., Luo Q., Huang Y., Li J., Ye W., Yan R., et al. Influenza neuraminidase mutations and resistance to neuraminidase inhibitors. Emerg. Microbes Infect. 13(1), 2429627, 2024. DOI: 10.1080/22221751.2024.2429627
4. Malik S., Asghar M., Waheed Y. Outlining recent updates on influenza therapeutics and vaccines: a comprehensive review. Vaccine X 17, 100452, 2024. DOI: 10.1016/j.jvacx.2024.100452
5. Melano I., Kuo L.L., Lo Y.C., Sung P.W., Tien N., Su W.C. Effects of basic amino acids and their derivatives on SARS-CoV-2 and influenza-A virus infection. Viruses 13(7), 1301, 2021. DOI: 10.3390/v13071301
6. Zhang Y., Cui W., Zhou H., Zou L., Wang Z., Cai K., et al. Enhancement of antioxidant activity, stability, and structure of heme-peptides by L-lysine. Foods 14(2), 192, 2025. DOI: 10.3390/foods14020192
7. Mailoo V.J., Rampes S. Lysine for Herpes simplex prophylaxis: a review of the evidence. Integr. Med. (Encinitas) 16(3), 42–46, 2017.
8. Sacramento C.Q., Marttorelli A., Fintelman-Rodrigues N., de Freitas C.S., de Melo G.R., Rocha M.E., et al. Aureonitol, a fungi-derived tetrahydrofuran, inhibits influenza replication by targeting its surface glycoprotein hemagglutinin. PLoS One 10(10), e0139236, 2015. DOI: 10.1371/journal.pone.0139236
9. Glanz V.Y., Myasoedova V.A., Grechko A.V., Orekhov A.N. Inhibition of sialidase activity as a therapeutic approach. Drug Des. Devel. Ther. 12, 3431–3437, 2018. DOI: 10.2147/DDDT.S176220
10. Guo Z., He Y., Xu J., Benegal A.N., Brody S.L., Vahey M.D. Neuraminidase activity modulates cellular coinfection during influenza A virus multicycle growth. mBio 14(3), e0359122, 2023. DOI: 10.1128/mbio.03591-22
